A Nature Communications study identified histone lactylation as an epigenetic mechanism that promotes immune evasion in pancreatic ductal adenocarcinoma by upregulating the chemokine CXCL1. Authors reported that tumor‑derived lactate modifies histones, altering transcriptional programs to recruit immunosuppressive cells and blunt anti‑tumor immunity. The work links tumor metabolism to chromatin remodeling and suggests new therapeutic angles combining metabolic inhibitors with immunotherapy. Researchers propose targeting lactate production or the lactylation pathway as a strategy to reverse immune suppression in pancreatic cancer.